Zdrowie i gospodarka · 29/09/2015

FDA Clears ORTHO EVRA for Continued Sale After Review

The FDA has determined that ORTHO EVRA, a transdermal hormone replacement therapy, will not be withdrawn from sale due to safety or effectiveness concerns, allowing the drug to remain on the market and continue to be approved for new applications.